Programme of Symposia
SYMPOSIA ON THE OCCASION OF EASD SEPTEMBER 17, 2007
- Optimal Glycaemic Control Under Scrutiny: What, Why and How? Eli Lilly & Company
- Beta-cell Failure in Type 2 Diabetes: An Inevitable Decline? Eli Lilly & Company
- Changing diabetes new solutions and best practices Novo Nordisk
- The modulating effects of GLP-1 in type 2 diabetes Novo Nordisk
- New insights to a modern basal insulin Novo Nordisk
- Lantus and Apidra: advanced managementstrategies for diabetic patients sanofi-aventis
- Rimonabant and global CMR risk management in patients with T2DM: How, when and why? sanofi-aventis
- Integrated Approaches to Diabetes Management Help Patients Do More Roche Diagnostics GmbH
- Exploring New Frontiers in Type 2 Diabetes Care: Latest Insights and Novel Pharmacotherapeutic Strategies Bristol-Myers Squibb Company and AstraZeneca
- Avoiding the Coming Catastrophe in Dyslipidemia Patients with Diabetes Through Inhibition of Cholesterol Absorption and Production Merck Sharp & Dohme/ Schering-Plough
- Islet Enhancer Vildagliptin: Mechanism of Action and Efficacy in T2DM Novartis Pharma AG
- Improving Glycaemic Control: Novel Concepts in the Treatment of Diabetes Pfizer
- Contemporary Issues in T2DM Management GlaxoSmithKline
- Achieving Glycemic Control Without Therapeutic Compromise: The Role of Sitagliptin A Novel Incretin Enhancer for Type 2 Diabetes Merck, Sharpe and Dohme
- Obesity is a Disease How Can the Risk be Managed? Merck, Sharpe and Dohme
- Transferring diabetes and CVD prevention into daily practice time to act now! Bayer Health Care
- Latent Autoimmune Diabetes in Adults: Prevalence and Characterization in Europ Sigma-Tau
- Addresing The Residual Risk of Type 2 Diabetes Takeda & Lilly Diabetes
- Challenges in Diabetes Care: Achieving the New Target Glucose Levels Pfizer
- Metformin Life begins at 50 Merck Serono
EASD NON-PROFIT SYMPOSIA SEPTEMBER 21 SEPTEMBER 23, 2007 32
- Technology and Therapeutics in Diabetes a concise update for clinicians and researchers
- Continuous glucose monitoring
- Implantable Insulin Pumps
- Continuous Subcutaneous Insulin Infusion
- Inhaled Insulin
MONDAY, SEPTEMBER 17, 2007 08.00 17.00 HOURS REMBRANDT HALL
OPTIMAL GLYCAEMIC CONTROL UNDER SCRUTINY: WHAT, WHY AND HOW?
Programme Chair: Professor Bruce Wolffenbuttel (The Netherlands)
08.00 08.05 hours
-
WELCOME
Dr Meng Tan (United States of America)
08.05 08.10 hours
-
INTRODUCTION
Professor Bruce Wolffenbuttel (The Netherlands)
08.10 08.50 hours
-
GLYCAEMIC CONTROL AND CARDIOVASCULAR DISEASE: WHAT DOES THE EVIDENCE SHOW? WHAT ANSWERS ARE ON THE HORIZON?
Dr Hertzel Gerstein (Canada)
08.50 09.40 hours
-
TARGET GLYCAEMIC CONTROL: TWO EXPERTS PERSPECTIVES
Dr John Buse (United States of America) and Dr Paul Jellinger (United States of America)
09.40 10.00 hours
-
BREAK
10.00 11.20 hours
-
BEYOND ORAL THERAPY: WHICH INSULIN TO START WITH?
Dr William Cefalu (United States of America), Professor Philip Home (United Kingdom), and Professor Bruce Wolffenbuttel (The Netherlands)
11.20 11.55 hours
-
INTENSIVE INSULIN THERAPY: WHY, WHEN, AND HOW TO USE IN TYPE 2 DIABETES
Dr Thomas Kunt (Germany)
11.55 12.00 hours
-
SUMMARY AND CONCLUSION
BETA-CELL FAILURE IN TYPE 2 DIABETES: AN INEVITABLE DECLINE?
Programme Chairs: Professor Hans Romijn (The Netherlands) and Dr Carol Wysham (United States of America)
12.00 13.30 hours
-
PROGRAMME LUNCHEON
Located in Hall 8
13.30 13.40 hours
-
WELCOME AND OPENING REMARKS
13.40 14.15 hours
-
BETA-CELL FUNCTION AND GENETICS IN TYPE 2 DIABETES
Dr Benoit Gauthier (Switzerland)
14.15 14.50 hours
-
DEVELOPMENT AND ROLE OF BETA-CELL DYSFUNCTION IN TYPE 2 DIABETES
Professor Stefano Del Prato (Italy)
14.50 15.15 hours
-
BREAK
15.15 15.55 hours
-
INCRETIN MIMETICS: INSIGHTS AND EVIDENCE
Professor Anthony Barnett (United Kingdom)
15.55 16.30 hours
-
EXENATIDE: US CLINICAL EXPERIENCE AND OUTCOMES
Dr Carol Wysham (United States of America)
16.30 17.00 hours
-
INTERACTIVE PANEL DISCUSSION
MONDAY, SEPTEMBER 17, 2007 08.30 15.30 HOURS KAREL APPEL HALL
CHANGING DIABETES NEW SOLUTIONS AND BEST PRACTICES
08.30 08.35 hours
-
OPENING AND WELCOME
Chairman: Dr. Robert Rizza (United States of America)
08.35 08.50 hours
-
SETTING THE STAGE THE CONSEQUENCES OF INACTION ARCHIMEDES DIABETES MODEL
Dr. Robert Rizza (United States of America)
08.50 09.35 hours
-
MANAGING DIABETES CHALLENGES: FROM A HEALTH CARE SYSTEM PERSPECTIVE
Prof. Elizabeth Teisberg (United States of America)
-
MANAGING DIABETES CHALLENGES: REDEFINING HEALTHCARE HOW CAN THIS BE DONE?
Prof. Elizabeth Teisberg (United States of America)
09.35 10.00 hours
-
MULTIDISCIPLINARY INTERVENTION MATTERS: THE STENO II POST TRIAL STUDY
Dr. Oluf Pedersen (Denmark)
10.00 10.20 hours
-
FROM A POLITICAL PERSPECTIVE: BUILDING POLITICAL MOMENTUM FOR CHANGE BARRIERS AND DRIVERS
Prof. Vincenzo Scotti (Italy)
10.20 10.40 hours
-
PANEL DISCUSSION
Dr. Robert Rizza (United States of America)
THE MODULATING EFFECTS OF GLP-1 IN TYPE 2 DIABETES
Chairman: Dr. M. Nauck (Germany)
11.00 11.05 hours
-
WELCOME FROM THE CHAIR
Dr. Michael Nauck (Germany)
11.05 11.25 hours
-
DEFINITION OF PROGRESSION OF TYPE 2 DIABETES
Dr. Vivian Fonseca (Italy)
11.25 11.50 hours
-
PHARMACOLOGY OF GLP-1-BASED THERAPIES
Dr. Jens Juul Holst (Denmark)
11.50 12.10 hours
-
MANAGING THE BETA-CELL WITH GLP-1
Dr. Boptist Gallwitz (Germany)
12.10 12.30 hours
-
MECHANISMS BEHIND GLP-1 INDUCED WEIGHT LOSS
Dr. Bernhard Zinman (Canada)
12.30 13.00 hours
-
LIRAGLUTIDE: A ONCE-DAILY HUMAN GLP-1 ANALOGUE
Dr. Michael Nauck (Germany)
NEW INSIGHTS TO A MODERN BASAL INSULIN
Chairman: Dr. Hans de Vries (The Netherlands)
13.45 13.50 hours
-
WELCOME FROM THE CHAIR
Dr. Hans de Vries (The Netherlands)
13.50 14.15 hours
-
LEVEMIR PHASE III PROGRAMME A SYSTEMATIC REVIEW AND META-ANALYSIS
Dr. Thomas Pieber (Austria)
14.15 14.40 hours
-
LEVEMIR TYPE 1 DIABETES TWO YEAR STUDY SUSTAINABLE GLYCAEMIC CONTROL AND LOW RISK OF HYPOGLYCAEMIA
Dr. Paul Bartley (Australia)
14.40 15.05 hours
-
EFFICACIOUS BASAL INSULIN INITIATION AND WEIGHT ADVANTAGE WITH LEVEMIR ONCE-DAILY USE IN T2DM
Dr. Athena Philis-Tsimikas (United States of America)
15.05 15.25 hours
-
REAL LIFE DATA FROM THE PREDICTIVE STUDY LEVEMIR IN BASAL ORAL THERAPY
Dr. Lena Landstedt-Hallin (Sweden)
15.25 15.30 hours
-
PERSPECTIVES
Dr. Hans de Vries (The Netherlands
MONDAY, SEPTEMBER 17, 2007 09.30 15.30 HOURS LOCATION: AMSTERDAM CONVENTION FACTORY
MORNING SESSION: LANTUS AND APIDRA: ADVANCED MANAGEMENT STRATEGIES FOR DIABETIC PATIENTS
Chairmen: George Alberti (United Kingdom) and Bryan Brewer (United States of America)
09.30 09.40 hours
-
INTRODUCTION
George Alberti (United Kingdom)
09.40 10.10 hours
-
MORE AMBITIOUS GOALS AND TOOLS FOR PATIENT MANAGEMENT Q & A
Vivian Fonseca (United States of America)
10.10 10.40 hours
-
TIMELY INITIATION OF BASAL INSULIN: FROM GUIDELINES TO PRACTICE Q & A
George Dailey (United States of America)
10.40 11.10 hours
-
APIDRA: A NEW GENERATION OF RAPID-ACTING INSULIN Q & A
David Owens (United Kingdom)
11.10 11.30 hours
-
COFFEE BREAK
11.30 12.00 hours
-
CONTROLLING THE DISEASE: FROM A BASAL PLUS TO A BASAL BOLUS STRATEGY Q & A
Martin Pfohl (Germany)
12.00 12.30 hours
-
SHIFTING THE DISEASE MANAGEMENT PARADIGM: FROM GLUCOSE TO CARDIOVASCULAR EVENT PREVENTION Q & A
Richard Nesto (United States of America)
12.30 13.30 hours
-
LUNCH BREAK
AFTERNOON SESSION: RIMONABANT AND GLOBAL CMR RISK MANAGEMENT IN PATIENTS WITH T2DM: HOW, WHEN AND WHY?
13.30 13.40 hours
-
INTRODUCTION
Bryan Brewer (United States of America)
13.40 14.10 hours
-
GLOBAL CARDIOMETABOLIC RISK FACTORS AND ABDOMINAL OBESITY: HOW INTRA-ABDOMINAL ADIPOSITY (ABDOMINAL OBESITY) AND OTHER METABOLIC DISORDERS CONTRIBUTE TO GLOBAL CMR Q & A
John Betteridge (United Kingdom)
14.10 14.40 hours
-
ENDOCANNABINOID SYSTEM: A NEW TARGET FOR MULTIPLE CARDIOMETABOLIC RISK MANAGEMENT Q & A
Rafael Maldonado (Spain)
14.40 15.10 hours
-
THE POTENTIAL OF RIMONABANT IN TYPE 2 DIABETES MANAGEMENT Q & A
Julio Rosenstock (United States of America)
15.10 15.30 hours
-
OVERALL CONCLUSIONS
George Alberti (United Kingdom) and Bryan Brewer (United States of America)
MONDAY, SEPTEMBER 17, 2007 14.00 16.30 HOURS ROOM N
INTEGRATED APPROACHES TO DIABETES MANAGEMENT HELP PATIENTS DO MORE
Chairmen: Philip Home (United Kingdom) and Frank Snoek (The Netherlands)
14.00 14.30 hours
-
REQUIREMENTS FOR SUCCESSFUL DIABETES MANAGEMENT
Philip Home (Newcastle, United Kingdom)
14.30 15.00 hours
-
NEW TOOLS TO ASSIST NON-INSULIN TREATED PATIENTS WITH DIABETES
William Polonsky (Delmar, United States of America)
15.00 15.30 hours
-
IMPROVED MANAGEMENT OF INSULIN TREATED PATIENTS WITH DIABETES
Satish Garg (Aurora, United States of America)
15.30 16.00 hours
-
OPTIMIZED DIABETES MANAGEMENT WITH INSULIN PUMP TREATMENT
Eric Renard (Montpellier, France)
16.00 16.30 hours
-
AWARENESS, EDUCATION, ASSISTANCE AND ACTION: WHAT TO DO?
Frank Snoek (Amsterdam, The Netherlands)
MONDAY, SEPTEMBER 17, 2007 08.00 11.30 HOURS VAN GOGH HALL
EXPLORING NEW FRONTIERS IN TYPE 2 DIABETES CARE: LATEST INSIGHTS AND NOVEL PHARMACOTHERAPEUTIC STRATEGIES
08.00 08.30 hours
-
BREAKFAST AND REGISTRATION
08.30 08.35 hours
-
WELCOME AND INTRODUCTION
Ralph A. DeFronzo (San Antonio, Texas, United States of America)
08.35 09.05 hours
-
ADVANCES IN THE UNDERSTANDING OF THE PATHOGENESIS OF TYPE 2 DM
Ralph A. DeFronzo (San Antonio, Texas, United States of America)
09.05 09.35 hours
-
REDUCING MICRO- AND MACROVASCULAR COMPLICATION OF TYPE 2 DM THROUGH IMPROVED GLUCOSE CONTROL
John Betteridge (London, England)
09.35 10.05 hours
-
LIPOTOXICITY AND GLUCOTOXICITY IN PROGRESSIVE BETA-CELL FAILURE IN TYPE 2 DM
Stefano Del Prato (Pisa, Italy)
10.05 10.35 hours
-
NOVEL TREATMENT STRATEGIES IN TYPE 2 DM: TARGETING THE INCRETIN AXIS
Jens J. Holst (Copenhagen, Denmark)
10.35 11.05 hours
-
NOVEL TREATMENT STRATEGIES IN TYPE 2 DM: SGLT-2 INHIBITORS
Ralph A. DeFronzo (San Antonio, Texas, United States of America)
11.05 11.30 hours
-
QUESTION & ANSWER SESSION
Faculty Panel
MONDAY, SEPTEMBER 17, 2007 10.30 12.00 HOURS MONDRIAAN HALL
AVOIDING THE COMING CATASTROPHE IN DYSLIPIDEMIA PATIENTS WITH DIABETES THROUGH INHIBITION OF CHOLESTEROL ABSORPTION AND PRODUCTION
Co-Chairmen: John Kastelein (The Netherlands) and Terje Pedersen (Norway)
10.30 10.35 hours
-
WELCOME AND OPENING REMARKS
John Kastelein (The Netherlands)
10.35 10.50 hours
-
THE CRISIS IN TREATMENT OF DYSLIPIDEMIC PATIENTS WITH DIABETES IS EXPLODING WITH THE NEW LDL-C GUIDELINES OF <70 MG/DL
Adrian Brady (United Kingdom)
10.50 11.20 hours
-
CLINICAL DEBATE: WHY LIPID MANAGEMENT SHOULD BE TREATED MORE IMPORTANTLY THAN GLUCOSE AND BLOOD PRESSURE MANAGEMENT
Lawrence Leiter (Canada) and John Kastelein (The Netherlands)
11.20 11.40 hours
-
INHIBITING CHOLESTEROL ABSORPTION AND PRODUCTION TO ACHIEVE SUPERIOR EFFICACY AND AVOIDING THE COMING CATASTROPHE FOR PATIENTS WITH DYSLIPIDEMIA AND DIABETES
Jurgen Schaefer (Germany)
11.40 11.55 hours
-
UPDATE AND UPCOMING NEWS ON THE ONGOING CARDIOVASCULAR OUTCOMES PROGRAM FOR EZETIMIBE
Terje Pedersen (Norway)
11.55 12.00 hours
-
CLOSING REMARKS
Terje Pedersen (Norway)
MONDAY, SEPTEMBER 17, 2007 10.00 12.00 HOURS JAN STEEN HALL
ISLET ENHANCER VILDAGLIPTIN: MECHANISM OF ACTION AND EFFICACY IN T2DM
Chairman: Professor Burkhard Gφke (Germany) (breakfast served outside the Jan Steen room 09.00-10.00)
10.00 10.05 hours
-
WELCOME AND INTRODUCTION
Burkhard Gφke (Munich, Germany)
10.05 10.30 hours
-
ISLET CELL FUNCTION: a- AND b-CELLS, PARTNERS TOWARD NORMOGLYCAEMIA
Burkhard Gφke (Munich, Germany)
10.30 10.55 hours
-
ISLET ENHANCER VILDAGLIPTIN: THE POWER OF MECHANISTIC EVIDENCE
Bo Ahrιn (Lund, Sweden)
10.55 11.15 hours
-
VILDAGLIPTIN: A NEW TREATMENT OPTION IN MONOTHERAPY
Julio Rosenstock (Dallas, Texas, United States of America)
11.15 11.45 hours
-
ROLE OF ISLET ENHANCER VILDAGLIPTIN IN COMBINATION THERAPY
Martin Fitchet, Novartis (East Hannover, New Jersey, United States of America)
11.45 12.00 hours
-
PANEL DISCUSSION
All faculty
MONDAY, SEPTEMBER 17, 2007 14.00 16.15 HOURS VAN GOGH HALL
IMPROVING GLYCAEMIC CONTROL: NOVEL CONCEPTS IN THE TREATMENT OF DIABETES
Chairmen: Lawrence Blonde (United States of America) and Jacques Philippe (Switzerland)
14.00 14.05 hours
-
WELCOME AND INTRODUCTION
Jacques Philippe (Switzerland)
14.05 14.35 hours
-
CAN WE NOW MEET THE UNMET NEED? THE PROMISE OF INHALED HUMAN INSULIN
Anthony Barnett (United Kingdom)
14.35 15.00 hours
-
INITIATING INSULIN THERAPY: THE ROLE OF INHADED HUMAN INSULIN
Lawrence Blonde (United States of America)
15.00 15.25 hours
-
BEYOND HbA1C IN TYPE 2 DIABETES MANAGEMENT
Louis Monnier (France)
15.25 15.50 hours
-
ARE NOVEL CONCEPTS IN GLYCAEMIC CONTROL CHANGING THE DIABETES LANDSCAPE IN EUROPE?
Jacques Philippe (Switzerland)
15.50 16.10 hours
-
QUESTIONS AND PANEL DISCUSSION
16.10 16.15 hours
-
CLOSING REMARKS
Lawrence Blonde (United States of America)
MONDAY, SEPTEMBER 17, 2007 16.00 18.00 HOURS JAN STEEN HALL
CONTEMPORARY ISSUES IN T2DM MANAGEMENT
Chairman: Giancarlo Viberti (London, United Kingdom)
16.00 16.05 hours
-
CHAIRMANS INTRODUCTION
Giancarlo Viberti (London, United Kingdom)
16.05 16.30 hours
-
THE PURSUIT OF LONG-TERM GLYCAEMIC CONTROL IN T2DM EVIDENCE FROM THE ADOPT TRIAL
Steven Kahn (Seattle, United States of America)
16.30 16.55 hours
-
DIABETES AND BONE PRACTICAL ASPECTS
Ove Tφrring (Stockholm, Sweden)
16.55 17.20 hours
-
GLITAZONES AND CARDIOVASCULAR RISK CONTEXT AND IMPLICATIONS
Richard Nesto (Burlington, United States of America)
17.20 17.45 hours
-
CURRENT ISSUES IN T2DM MANAGEMENT WEIGHING UP THE EVIDENCE ON EFFICACY AND SAFETY
Philip Home (Newcastle, United Kingdom)
17.45 18.00 hours
-
CHAIRMANS CONCLUSION AND PANEL DISCUSSION
Giancarlo Viberti (London, United Kingdom)
MONDAY, SEPTEMBER 17, 2007 13.00 15.00 HOURS MONDRIAAN HALL
ACHIEVING GLYCEMIC CONTROL WITHOUT THERAPEUTIC COMPROMISE: THE ROLE OF SITAGLIPTIN A NOVEL INCRETIN ENHANCER FOR TYPE 2 DIABETES
Chairman: Professor Michaela Diamant (The Netherlands)
13.00 13.05 hours
-
WELCOME & INTRODUCTION
Michaela Diamant (The Netherlands)
13.05 13.35 hours
-
THE CHANGING LANDSCAPE IN TYPE 2 DIABETES MANAGEMENT
Russell Scott (New Zealand)
13.35 14.05 hours
-
INTEGRATING INCRETIN-BASED THERAPIES IN THE TREATMENT OF TYPE 2 DIABETES
Carolyn Deacon (Denmark)
14.05 14.35 hours
-
ACHIEVING THERAPEUTIC GOALS WITH SITAGLIPTIN
Michael Nauck (Germany)
14.35 14.55 hours
-
QUESTIONS & ANSWERS / FACULTY PANEL DISCUSSION
14.55 15.00 hours
-
CONCLUDING REMARKS
Michaela Diamant (The Netherlands)
MONDAY, SEPTEMBER 17, 2007 16.00 18.00 HOURS MONDRIAAN HALL
OBESITY IS A DISEASE HOW CAN THE RISK BE MANAGED?
Chairman: Arne Astrup (Denmark)
16.00 16.05 hours
-
WELCOME AND OPENING REMARKS
Arne Astrup (Denmark)
16.05 16.20 hours
-
OBESITY IS A DISEASE!
Luc Van Gaal (Belgium)
16.20 16.40 hours
-
WEIGHT LOSS AND RISK REDUCTION
Arya Sharma (Canada)
16.40 17.00 hours
-
THERAPEUTIC INTERVENTIONS FOR WEIGHT LOSS
Nick Finer (United Kingdom)
17.00 17.20 hours
-
CB1 RECEPTOR INVERSE AGONISTS THE NEW APPROACH
John Blundell (United Kingdom)
17.20 17.45 hours
-
TARANABANT A NOVEL CB1 RECEPTOR INVERSE AGONIST
Tung Fong (United States of America)
17.45 18.00 hours
-
QUESTIONS & ANSWERS/CLOSING REMARKS
Arne Astrup (Denmark)
MONDAY, SEPTEMBER 17, 2007 13.15 16.00 HOURS ROOM A
TRANSFERRING DIABETES AND CVD PREVENTION INTO DAILY PRACTICE TIME TO ACT NOW!
Chairman: R Holman (United Kingdom)
13.15 13.20 hours
-
WELCOME
R. Holman (United Kingdom)
13.20 13.40 hours
-
TREATING AND PREVENTING DYSGLYCAEMIA AND CVD UNDERSTANDING THE CHALLENGE
E. Standl (Germany)
13.40 14.00 hours
-
THE DEADLY DUO DYSGLYCAEMIA AND CVD RECOMMENDATIONS FROM CURRENT GUIDELINES
L. Rydιn (Sweden)
-
TAKING DIABETES AND CVD PREVENTION INTO DAILY PRACTICE REGIONAL PERSPECTIVES ONIMPLEMENTATION
14.00 14.15 hours
-
EUROPEAN EXPERIENCE
J. Tuomilehto (Finland)
14.15 14.30 hours
-
ASIAN EXPERIENCE
J. Shaw (Australia)
14.30 14.45 hours
-
NORTH AMERICAN EXPERIENCE
J.-L. Chiasson (Canada)
14.45 15.00 hours
-
LATIN AMERICAN EXPERIENCE
J. Rosas (Mexico)
15.00 15.20 hours
-
MANAGING DYSGLYCAEMIA AND CVD EXPLORING CURRENT TREATMENT OPTIONS
J.-L. Chiasson (Canada)
15.20 15.40 hours
-
CVD RISK REDUCTION IN PREDIABETES IMPACT OF RECENT STUDIES AND OF THE ACARBOSE CARDIOVASCULAR EVALUATION (ACE) TRIAL
R. Holman (United Kingdom)
15.40 15.55 hours
-
DISCUSSION
15.55 16.00 hours
-
SUMMARY AND CLOSE
R. Holman (United Kingdom)
MONDAY, SEPTEMBER 17, 2007 09.15 13.00 HOURS ROOM B
LATENT AUTOIMMUNE DIABETES IN ADULTS: PREVALENCE AND CHARACTERIZATION IN EUROPE
Chairmen: Professor RDG Leslie and Professor P Pozzilli
09.15 09.30 hours
-
WELCOME
09.30 10.10 hours
-
THE BOTNIA STUDY
Dr Tiinamaija Tuomi (Finland)
10.10 10.50 hours
-
THE UKPDS
Professor Timothy Davis (Australia)
10.50 11.30 hours
-
THE NIRAD STUDY
Professor Raffaella Buzzetti (Italy)
11.30 12.10 hours
-
THE ACTION LADA PROJECT
Dr Nanette Schloot (Germany)
12.10 13.00 hours
-
OUTSTANDING ISSUES AND FUTURE PLANS: DISCUSSION
MONDAY, SEPTEMBER 17, 2007 15.50 18.00 HOURS ROOM B
ADDRESSING THE RESIDUAL RISK OF TYPE 2 DIABETES
Co-chairmen: Professor John Betteridge (United Kingdom) and Professor Ralph DeFronzo (United States of America)
15.50 16.05 hours
-
CHAIRMANS INTRODUCTION
Professor Ralph DeFronzo (United States of America)
16.05 16.30 hours
-
OPTIMAL MANAGEMENT OF DYSLIPIDAEMIA IN TYPE 2 DIABETES
Professor John Betteridge (United Kingdom)
16.30 16.55 hours
-
CARDIOVASCULAR COMPLICATIONS IN TYPE 2 DIABETES: A CARDIOLOGISTS VIEW
Professor Bob Chilton (United States of America)
16.55 17.20 hours
-
TREATING TO TARGET
Professor Jochen Seufert (Germany)
17.20 17.45 hours
-
PREVENTING DIABETIC RETINOPATHY
Professor Massimo Porta (Italy)
17.45 18.00 hours
-
CHAIRMANS CONCLUSIONS
Professor John Betteridge (United Kingdom)
MONDAY, SEPTEMBER 17, 2007 11.00 13.00 HOURS ROOM A
CHALLENGES IN DIABETES CARE: ACHIEVING THE NEW TARGET GLUCOSE LEVELS
Co-Chairmen: Satish K. Garg (United States of America) & Richard M. Bergenstal (United States of America)
11.00 11.05 hours
-
WELCOME AND INTRODUCTIONS
Satish K. Garg (United States of America)
11.05 11.40 hours
-
OPTIMIZING INSULIN THERAPY TO ATTAIN TARGET GLUCOSE CONTROL
Satish K. Garg (United States of America)
11.40 12.15 hours
-
THE INTEGRATIVE APPROACH TO OPTIMIZING PRANDIAL GLUCOSE CONTROL
Richard M. Bergenstal (United States of America)
12.15 12.45 hours
-
CASE PRESENTATIONS: PRACTICAL APPROACH TO OPTIMAL GLYCEMIC CONTROL BASED ON PATIENT CHARACTERISTICS AND PATIENT PREFERENCE
-
THERAPEUTIC OPTIONS FOR THE PATIENT WITH TYPE 2 DIABETES
Richard M. Bergenstal (United States of America) CASE 1: The Patient on basal insulin CASE 2: The Patient failing oral medication
-
THERAPEUTIC OPTIONS FOR THE PATIENT WITH TYPE 1 DIABETES
Satish K. Garg (United States of America) CASE 3: The patient unwilling to parenterally administer insulin
12.45 13.00 hours
-
QUESTIONS & ANSWERS AND ADJOURNMENT
Satish K. Garg (United States of America) & Richard M. Bergenstal (United States of America)
MONDAY, SEPTEMBER 17, 2007 16.00 18.00 HOURS MARRIOTT HOTEL
METFORMIN LIFE BEGINS AT 50
Chairmen: Gιrard Slama & Ian W. Campbell
16.00 16.05 hours
-
INTRODUCTION AND WELCOME
Gιrard Slama (Paris, France)
16.05 16.20 hours
-
METFORMIN THROUGH FIVE DECADES A HISTORICAL PERSPECTIVE
Harry Howlett (London, United Kingdom)
16.20 16.35 hours
-
ACTIONS OF METFORMIN TREATING THE PATHOPHYSIOLOGY OF TYPE 2 DIABETES
Cliff Bailey (Birmingham, United Kingdom)
16.35 16.50 hours
-
VASCULO-PROTECTIVE BENEFITS OF METFORMIN IN REDUCING CV RISK
Juliana Chan (Hong Kong)
16.50 17.05 hours
-
METFORMIN: BENCHMARK FOR ORAL ANTIDIABETIC AGENTS
Patrick Ritz (Angers, France)
17.05 17.20 hours
-
METFORMIN: THERAPEUTIC POTENTIAL BEYOND DIABETES
Ian W. Campbell (St Andrews, United Kingdom)
17.20 17.35 hours
-
METFORMIN: CORE THERAPY IN MANAGEMENT GUIDELINES FOR TYPE 2 DIABETES WORLDWIDE
Jaime Davidson (Dallas, United States of America)
17.35 17.55 hours
-
PANEL DISCUSSION
17.55 18.00 hours
-
CONCLUDING REMARKS
Ian W. Campbell
EASD NON-PROFIT SYMPOSIA
SEPTEMBER, 21-23, 2007
TECHNOLOGY AND THERAPEUTICS IN DIABETES A CONCISE UPDATE FOR CLINICIANS AND RESEARCHERS
FRIDAY, SEPTEMBER 21, 2007 ZWOLLE 16.00 23.00 HOURS DE NIEUWE BUITENSOCIETEIT
16.00 18.00 hours
-
REGISTRATION
18.00 18.15 hours
-
WELCOME
Dr. A.J. Spijker
18.15 19.00 hours
-
TECHNOLOGY FROM HERE TO ETERNITY
Chairmen: Dr. Kowalski and Dr. Spijker J-L Selam (United States of America)
20.00 23.00 hours
-
WELCOME RECEPTION
SATURDAY, SEPTEMBER 22, 2007 ZWOLLE 08.30 18.30 HOURS DE NIEUWE BUITENSOCIETEIT
CONTINUOUS GLUCOSE MONITORING
Chairman: Bolinder (Sweden)
08.30 09.00 hours
-
OVERVIEW OF CONTINUOUS GLUCOSE MONITORING (CGM)
Bruce Buckingham (United States of America)
09.00 10.00
-
ACCURACY OF CGM
J.H. de Vries (Amsterdam, The Netherlands) and B. Kovatchev (Unites States of America)
10.00 10.30 hours
-
BREAK
10.30 11.30 hours
-
RESULTS OF DEVICES AND FUTURE DEVELOPMENTS :
Glucoday 15 min. Dexcom 15 min. Guardian 15 min. Freestyle 15 min. A. Marcus
-
IMPLANTABLE INSULIN PUMPS
Chairmen: J-L Selam and Van Ballegooie
11.30 12.00 hours
-
STATE OF THE ART LECTURE, EVADIAC REPORT
H. Hanaire (France)
12.00 12.30 hours
-
THE ZWOLLE STUDY, CIPII VS CSII
H.J.G. Bilo (The Netherlands)
12.30 13.00 hours
-
THE FUTURE OF CIPII
C. Saudek (United States of America)
13.00 14.00 hours
-
LUNCH BREAK
CLOSING THE LOOP
Chairmen: Massi Benedetti and Sandek
14.00 14.30 hours
-
EXPERIENCE WITH CLOSED LOOP SYSTEM
B. Kovatchev (United States of America)
PANEL DISCUSSION
Chairmen: Massi Benedetti and Sandek
14.30 14.45 hours
-
PANEL DISCUSSION ON GLUCOSE, MONITORING AND CLOSING THE LOOP
A. Kowalski
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION
Chairmen: Massi Benedetti and Kowalski
14.45 15.15 hours
-
INTELLIGENT USE OF MDI AND CSII TO MIMIC PHYSIOLOGY OF INSULIN/GLUCOSE DYNAMICS
G. Bolli (Italy)
15.15 16.00 hours
-
THE FUTURE OF CSII :
Medtronic vision 15 min. Roche vision 15 min. A. Marcus Deltec vision 15 min.
16.00 16.15 hours
-
TEA BREAK
16.15 18.00 hours
-
NEW DEVELOPMENTS
Chair: V. Vague / M. Pinget
-
SESSIONS ON : ENDO CANNABOID RECEPTORS INCRETINS / DPP-4 INHIBITORS NEW INSULINS PEN-LIKE DEVICES
18.00 18.30 hours
-
PRESIDENTIAL LECTURE
Chairman: G.Bolli
-
BIO-ARTIFICIAL PANCREAS
M. Pinget (France)
19.00 hours
-
DINNER PARTY IN 18TH CENTURY ESTATE IN THE DUTCH COUNTRYSIDE, TOGETHER WITH OPERA DELLA CASA
SUNDAY, SEPTEMBER 23, 2007 ZWOLLE 08.30 14.00 HOURS DE NIEUWE BUITENSOCIETEIT
INHALED INSULIN
Chairman: G.Bolli
08.30 09.00 hours
-
STATE OF THE ART
09.00 11.00 hours
-
FUTURE DEVELOPMENTS THE VISION OF :
Pfizer 15 min Eli Lilly 15 min P. Maheux D. Muchmore Mannkind 15 min Novo Nordisk 15 min Sanofi-Aventis 15 min
11.00 11.30 hours
-
COFFEE BREAK
CLOSING LECTURE
Chairmen: Van Ballegooie and Spijker
11.30 12.00 hours
-
CLOSED LOOP IN THE FUTURE
A. Kowalski (United States of America)
12.00 12.15 hours
-
CLOSING OF THE SYMPOSIUM
A. Kowalski (United States of America)
12.15 14.00 hours
-
LUNCH AND DEPARTURE